Payment overview · 2025
General Payments
$1,424.23
75 reported records · 24 companies
Healthcare provider profile · identity verified
Sergei V Chekov, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PHILADELPHIA, PA · NPI 1265470306
Verified facts
What the public records show
CMS Open Payments records show Sergei V Chekov, MD received $1,424.23 in general payments during 2025 across 75 reported records.
ABBVIE INC. accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Gemtesa, Linzess, Nurtec Odt, Ozempic, Trelegy Ellipta, Trulance, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 777 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 887 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 478 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $273.20 | 19.2% | 14 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $238.74 | 16.8% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.84 | 7.0% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $88.73 | 6.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $78.08 | 5.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.43 | 5.0% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $67.21 | 4.7% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $67.00 | 4.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.27 | 3.5% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $48.11 | 3.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.20 | 3.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.10 | 2.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.84 | 2.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.73 | 1.9% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $26.30 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.56 | 1.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.45 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.88 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.69 | 1.4% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $19.17 | 1.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.66 | 1.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.35 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.35 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.34 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,424.23 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $238.74 | 18 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $196.24 | 10 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $156.67 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $88.73 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $78.08 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.87 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $70.43 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $67.21 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $67.00 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.52 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.27 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $48.11 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.84 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.84 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 777 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 478 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 167 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 887 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 202 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
777 | 97 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
887 | 99 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
325 | 32 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
202 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
205 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
478 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
167 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 2193 | 259 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1768 | 206 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1695 | 202 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1689 | 230 |
| Losartan Potassium | Losartan Potassium | 1651 | 209 |
| Furosemide | Furosemide | 1446 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1362 | 145 |
| Omeprazole | Omeprazole | 1298 | 150 |
| Diclofenac Sodium | Diclofenac Sodium | 1230 | 197 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1128 | 118 |
| Gabapentin | Gabapentin | 1073 | 138 |
| Metoprolol Succinate | Metoprolol Succinate | 1061 | 129 |
| Metformin Hcl | Metformin Hcl | 935 | 107 |
| Alprazolam | Alprazolam | 932 | 126 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 917 | 105 |
| Fluticasone Propionate | Fluticasone Propionate | 916 | 192 |
| Linzess | Linaclotide | 887 | 99 |
| Escitalopram Oxalate | Escitalopram Oxalate | 830 | 102 |
| Donepezil Hcl | Donepezil Hcl | 811 | 89 |
| Ibuprofen | Ibuprofen | 796 | 130 |
| Tamsulosin Hcl | Tamsulosin Hcl | 784 | 93 |
| Creon | Lipase/Protease/Amylase | 777 | 97 |
| Clonidine Hcl | Clonidine Hcl | 764 | 102 |
| Vascepa | Icosapent Ethyl | 741 | 82 |
| Valsartan | Valsartan | 710 | 94 |
| Hydralazine Hcl | Hydralazine Hcl | 695 | 78 |
| Lisinopril | Lisinopril | 620 | 85 |
| Zolpidem Tartrate | Zolpidem Tartrate | 608 | 82 |
| Meclizine Hcl | Meclizine Hcl | 552 | 95 |
| Atenolol | Atenolol | 548 | 59 |
| Ropinirole Hcl | Ropinirole Hcl | 489 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 479 | 57 |
| Eliquis | Apixaban | 478 | 50 |
| Meloxicam | Meloxicam | 465 | 64 |
| Ketoconazole | Ketoconazole | 456 | 63 |
| Ezetimibe | Ezetimibe | 445 | 49 |
| Montelukast Sodium | Montelukast Sodium | 444 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 441 | 55 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 421 | 59 |
| Famotidine | Famotidine | 410 | 54 |
| Allopurinol | Allopurinol | 403 | 50 |
| Simvastatin | Simvastatin | 400 | 47 |
| Doxazosin Mesylate | Doxazosin Mesylate | 399 | 48 |
| Potassium Chloride | Potassium Chloride | 378 | 48 |
| Dexlansoprazole Dr | Dexlansoprazole | 373 | 41 |
| Dicyclomine Hcl | Dicyclomine Hcl | 368 | 54 |
| Trazodone Hcl | Trazodone Hcl | 363 | 38 |
| Clonazepam | Clonazepam | 359 | 37 |
| Carvedilol | Carvedilol | 357 | 44 |
| Nifedipine Er | Nifedipine | 342 | 41 |
| Ranolazine Er | Ranolazine | 325 | 30 |
| Synthroid | Levothyroxine Sodium | 325 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 324 | 28 |
| Metformin Hcl Er | Metformin Hcl | 322 | 42 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 311 | 88 |
| Lorazepam | Lorazepam | 308 | 37 |
| Procto-Med Hc | Hydrocortisone | 305 | 60 |
| Nitroglycerin | Nitroglycerin | 301 | 58 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 296 | 31 |
| Mirtazapine | Mirtazapine | 287 | 32 |
| Sertraline Hcl | Sertraline Hcl | 268 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 263 | 28 |
| Memantine Hcl | Memantine Hcl | 262 | 28 |
| Lidocaine | Lidocaine | 258 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 255 | 51 |
| Alendronate Sodium | Alendronate Sodium | 255 | 27 |
| Tramadol Hcl | Tramadol Hcl | 251 | 45 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 231 | 60 |
| Finasteride | Finasteride | 230 | 27 |
| Januvia | Sitagliptin Phosphate | 222 | 34 |
| Azithromycin | Azithromycin | 218 | 170 |
| Celecoxib | Celecoxib | 210 | 30 |
| Colchicine | Colchicine | 210 | 31 |
| Glipizide Er | Glipizide | 207 | 24 |
| Xarelto | Rivaroxaban | 205 | 21 |
| Ammonium Lactate | Ammonium Lactate | 202 | 44 |
| Zenpep | Lipase/Protease/Amylase | 202 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 183 | 19 |
| Latanoprost | Latanoprost | 179 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 178 | 20 |
| Methylprednisolone | Methylprednisolone | 178 | 128 |
| Ventolin Hfa | Albuterol Sulfate | 175 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 170 | 42 |
| Ondansetron Hcl | Ondansetron Hcl | 169 | 30 |
| Gemtesa | Vibegron | 167 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 165 | 19 |
| Proctozone-Hc | Hydrocortisone | 160 | 48 |
| Myrbetriq | Mirabegron | 157 | 22 |
| Hydrocortisone | Hydrocortisone | 156 | 37 |
| Ibu | Ibuprofen | 155 | 39 |
| Glipizide | Glipizide | 152 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 148 | 114 |
| Citalopram Hbr | Citalopram Hydrobromide | 147 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 146 | 34 |
| Mupirocin | Mupirocin | 144 | 38 |
| Risperidone | Risperidone | 136 | 19 |
| Clotrimazole | Clotrimazole | 135 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 13 |
| Azelastine Hcl | Azelastine Hcl | 131 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 130 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 128 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 13 |
| Labetalol Hcl | Labetalol Hcl | 125 | 15 |
| Nystatin | Nystatin | 125 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 119 | 21 |
| Memantine Hcl Er | Memantine Hcl | 118 | 16 |
| Tradjenta | Linagliptin | 115 | 14 |
| Loperamide | Loperamide Hcl | 114 | 37 |
| Restasis | Cyclosporine | 113 | 12 |
| Temazepam | Temazepam | 113 | 23 |
| Irbesartan | Irbesartan | 112 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 112 | 16 |
| Warfarin Sodium | Warfarin Sodium | 110 | 11 |
| Chlorthalidone | Chlorthalidone | 109 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 107 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 106 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 106 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 105 | 11 |
| Glimepiride | Glimepiride | 103 | 12 |
| Lansoprazole | Lansoprazole | 102 | 15 |
| Enalapril Maleate | Enalapril Maleate | 98 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 98 | suppressed |
| Naproxen | Naproxen | 96 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 94 | 15 |
| Dutasteride | Dutasteride | 92 | 12 |
| Prednisone | Prednisone | 90 | 64 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 88 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 12 |
| Cyclosporine | Cyclosporine | 86 | 22 |
| Jardiance | Empagliflozin | 82 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 81 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 79 | 11 |
| Bumetanide | Bumetanide | 79 | 12 |
| Repaglinide | Repaglinide | 78 | 11 |
| Levetiracetam | Levetiracetam | 77 | suppressed |
| Ozempic | Semaglutide | 77 | suppressed |
| Spironolactone | Spironolactone | 77 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 76 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 72 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 70 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 69 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 68 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 66 | 20 |
| Farxiga | Dapagliflozin Propanediol | 64 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 63 | suppressed |
| Ssd | Silver Sulfadiazine | 62 | 16 |
| Metronidazole | Metronidazole | 60 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 60 | suppressed |
| Pregabalin | Pregabalin | 59 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Ciclopirox | Ciclopirox | 55 | 15 |
| Doxepin Hcl | Doxepin Hcl | 53 | suppressed |
| Olanzapine | Olanzapine | 53 | suppressed |
| Fenofibrate | Fenofibrate | 51 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 49 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 49 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 49 | 34 |
| Ondansetron Odt | Ondansetron | 49 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 49 | 12 |
| Terazosin Hcl | Terazosin Hcl | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 48 | 11 |
| Lovastatin | Lovastatin | 47 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 39 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 43 | 18 |
| Arnuity Ellipta | Fluticasone Furoate | 43 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Febuxostat | Febuxostat | 41 | suppressed |
| Cilostazol | Cilostazol | 40 | suppressed |
| Trulance | Plecanatide | 40 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 39 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 39 | suppressed |
| Telmisartan | Telmisartan | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 29 |
| Valacyclovir | Valacyclovir Hcl | 38 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 37 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 15 |
| Bupropion Hcl | Bupropion Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 30 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Nyamyc | Nystatin | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Lumigan | Bimatoprost | 32 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 32 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Dexilant | Dexlansoprazole | 30 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Erythromycin | Erythromycin Base | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Cefdinir | Cefdinir | 28 | 25 |
| Digoxin | Digoxin | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 28 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Ambien | Zolpidem Tartrate | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 26 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 26 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 26 | 15 |
| Ramipril | Ramipril | 26 | suppressed |
| Seroquel Xr | Quetiapine Fumarate | 26 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 26 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Zaleplon | Zaleplon | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Enulose | Lactulose | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 24 | suppressed |
| Mesalamine Dr | Mesalamine | 23 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 23 | 18 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 20 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Metolazone | Metolazone | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Proctosol-Hc | Hydrocortisone | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Bystolic | Nebivolol Hcl | 14 | suppressed |
| Disopyramide Phosphate | Disopyramide Phosphate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Flunisolide | Flunisolide | 13 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Piroxicam | Piroxicam | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Alrex | Loteprednol Etabonate | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,424.23 · 75 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, Auvelity, CONTRAVE, CREON, Cologuard Collection Kit, ELIQUIS, GEMTESA, IBSRELA, Kerendia, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, ONZETRA XSAIL, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, RELISTOR, REPATHA, REXULTI, Rybelsus, SPRAVATO, Symbravo, TRELEGY ELLIPTA, TRULANCE, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error